We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Israeli drugmaker Protalix has filed an NDA for its Gaucher’s disease treatment taliglucerase alfa with the FDA and a proposed pediatric investigation
plan with the European Medicines Agency (EMEA).